EUVIMEDEUVIMED entdecken
Crossref

Intranasal phage therapy overcomes antibody neutralization challenges in pulmonary Pseudomonas aeruginosa infections

Dhammika Leshan Wannigama, Jingping Shao, Hongya Sun, Yangzhong Wang, Cameron Hurst, Peter N Monk, Mohan Amarasiri, Phatthranit Phattharapornjaroen, William Graham Fox Ditcham, Thin Sandi Htun, Sirirat Luk-In, Yoshitaka Shimotai und 15 weitere

Archives of Microbiology · 2025

DOI: 10.1007/s00203-025-04526-6 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Archives of Microbiology, 2025. Verfasst von Dhammika Leshan Wannigama und 26 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, Faculty of Medicine, Yamagata University, Yamagata, Japan. leshanwannigama@med.id.yamagata-u.ac.jp. Hauptthemen laut MEDLINE: Pseudomonas aeruginosa, Pseudomonas Infections, Phage Therapy, Antibodies, Bacterial. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 35 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Phage therapy is a promising approach against multidrug-resistant infections, yet systemic administration can lead to incomplete cures. We investigated the distribution, immune responses, and efficacy of the therapeutic phage KPP10 delivered via intranasal or intraperitoneal (IP) routes in murine Pseudomonas aeruginosa lung infection models. Intranasal pre-treatment achieved markedly higher localization of KPP10 in the lungs and bronchoalveolar compartment compared to IP delivery. Intranasal administration elicited minimal systemic antibody responses, whereas IP injection triggered significant IgG, IgM, and IgA production. Antibody responses did not differ significantly between doses. In acute and chronic infection models, intranasal KPP10 significantly improved survival (p < 0.01) and reduced lung bacterial loads relative to IP injection. Importantly, IP treatment was associated with bacterial rebound after day 14 in chronic infection, whereas intranasal dosing sustained bacterial clearance. These findings demonstrate that intranasal delivery enhances pulmonary localization, minimizes antibody-mediated neutralization, and provides superior therapeutic efficacy, highlighting its potential as a more effective route for phage therapy against P. aeruginosa lung infections.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pseudomonas aeruginosaPseudomonas InfectionsPhage TherapyAntibodies, BacterialAntibodies, NeutralizingPseudomonas PhagesAnimalsAdministration, IntranasalMiceFemaleLungDisease Models, Animal

Stichwörter der Autor:innen

Antibody-mediated neutralizationChronic pulmonary Pseudomonas aeruginosa infectionsIntranasal phage treatment

Substanzen

Antibodies, BacterialAntibodies, Neutralizing

Autor:innen und Institutionen

  • Department of Infectious Diseases, Faculty of Medicine, Yamagata University, Yamagata, Japan. leshanwannigama@med.id.yamagata-u.ac.jp.
  • Department of Infectious Diseases and Infection Control, Yamagata Prefectural Central Hospital, Yamagata, Japan. leshanwannigama@med.id.yamagata-u.ac.jp.
  • Pathogen Hunter's Research Team, Department of Infectious Diseases and Infection Control, Yamagata Prefectural Central Hospital, Yamagata, Japan. leshanwannigama@med.id.yamagata-u.ac.jp.
  • School of Medicine, Faculty of Health and Medical Sciences, The University of Western Australia, Nedlands, WA, Australia. leshanwannigama@med.id.yamagata-u.ac.jp.
  • Yamagata Prefectural University of Health Sciences, Kamiyanagi, Yamagata, 990-2212, Japan. leshanwannigama@med.id.yamagata-u.ac.jp.
  • Biofilms and Antimicrobial Resistance Consortium of ODA receiving countries, The University of Sheffield, Sheffield, UK. leshanwannigama@med.id.yamagata-u.ac.jp.

Zitieren

APA

Wannigama, D. L., Shao, J., Sun, H., Wang, Y., Hurst, C., Monk, P. N., Amarasiri, M., Phattharapornjaroen, P., Ditcham, W. G. F., Htun, T. S., Luk-In, S., Shimotai, Y., Ngamwongsatit, N., Ishikawa, H., Ragupathi, N. K. D., Pletzer, D., Kanjanabuch, T., Khatib, A., Miyanaga, K., …, & Hamamoto, H. (2025). Intranasal phage therapy overcomes antibody neutralization challenges in pulmonary Pseudomonas aeruginosa infections. Archives of Microbiology. https://doi.org/10.1007/s00203-025-04526-6

Vancouver

Wannigama DL, Shao J, Sun H, Wang Y, Hurst C, Monk PN, et al. Intranasal phage therapy overcomes antibody neutralization challenges in pulmonary Pseudomonas aeruginosa infections. Archives of Microbiology. 2025. doi:10.1007/s00203-025-04526-6

BibTeX
@article{Wannigama2025,
  author = {Wannigama, Dhammika Leshan and Shao, Jingping and Sun, Hongya and Wang, Yangzhong and Hurst, Cameron and Monk, Peter N and Amarasiri, Mohan and Phattharapornjaroen, Phatthranit and Ditcham, William Graham Fox and Htun, Thin Sandi and Luk-In, Sirirat and Shimotai, Yoshitaka and Ngamwongsatit, Natharin and Ishikawa, Hitoshi and Ragupathi, Naveen Kumar Devanga and Pletzer, Daniel and Kanjanabuch, Talerngsak and Khatib, Aisha and Miyanaga, Kazuhiko and Cui, Longzhu and Shibuya, Kenji and Higgins, Paul G and Kicic, Anthony and Hongsing, Parichart and Zhao, Jinxin and Abe, Shuichi and Hamamoto, Hiroshi},
  title = {Intranasal phage therapy overcomes antibody neutralization challenges in pulmonary Pseudomonas aeruginosa infections},
  journal = {Archives of Microbiology},
  year = {2025},
  doi = {10.1007/s00203-025-04526-6}
}
Kostenlos starten →